• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Immunovirotherapy showed acceptable adverse-event profile in pediatric high-grade gliomas

bySze Wah Samuel ChanandHarsh Shah
April 20, 2021
in Neurology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with herpes simplex virus type 1 oncolytic virotherapy was shown not to demonstrate serious adverse events in pediatric patients with high-grade gliomas.

2. The oncolytic virotherapy was shown to increase the number of tumor-infiltrating lymphocytes.

Evidence Rating Level: 2 (Good)   

Study Rundown: Pediatric high-grade glioma remains to have a grim prognosis despite the current standard of care consisting of radiotherapy and chemotherapy. High-grade gliomas characteristically have a low mutational burden with few tumor-infiltrating lymphocytes. As such, this study evaluated the safety of an oncolytic herpes simplex virus type 1 (HSV-1) termed G207 on recurrent high-grade glioma. The study determined viral replication was disabled in normal cells but retained in tumor cells. There was no evidence of viral shedding or viremia. Furthermore, no high-grade adverse events were attributable to G207. Finally, available pathological treatments post-treatment revealed increases in tumor-infiltrating lymphocytes. The study was limited by the use of the immunotherapy Response Assessment in Neuro-Oncology criteria to determine the radiographic response in the tumor. Nonetheless, the study’s results were significant, as the trial provided preliminary evidence to suggest that oncolytic viruses have an acceptable adverse-event profile.

Click here to read the study in the NEJM

Relevant Reading: Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis

RELATED REPORTS

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas

In-Depth [prospective cohort]: In this phase 1 safety trial, 12 pediatric patients were enrolled in the study. Patients included in the study were between 3 and 18 years of age with a malignant supratentorial brain tumor of 1.0 cm or larger that has progressed after surgery radiotherapy, or chemotherapy. Patients with tumors requiring cerebellar, brainstem, ventricular inoculation were excluded from the study. The primary outcome was determining the safety profile of G207 and a response assessment based on magnetic resonance imaging. The median overall survival was 12.2 months (95% confidence interval [CI], 8.0 to 16.4 months). All adverse events related to G207 were assessed to be grade 1, and no serious adverse events were assessed by the investigators to be related to G207. There was no distinct pattern of adverse events in this cohort. Stable disease was seen in 7 of 12 patients at 1 month (58%), 4 of 11 patients at 3 months (27%), and 2 of 11 patients at 12 months (18%). In 4 patients who had pathological samples for examination post-treatment, there were increases in CD3+, CD4+, and CD8+ tumor-infiltrating lymphocytes compared to pre-treatment. In general, G207 has a reasonable safety profile in the treatment of pediatric high-grade gliomas.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: gliomaherpes simplex virus type 1high-gradeimmunovirotherapy
Previous Post

Use of bamlanivimab for patients with mild to moderate COVID-19 infection

Next Post

Psilocybin does not significantly improve depressive scores compared to escitalopram

RelatedReports

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
StudyGraphics

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

August 25, 2023
Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]
Oncology

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

August 21, 2023
Combined MRI and NIH stroke scores may predict stroke prognosis
Neurology

Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas

December 1, 2021
#VisualAbstract: Occult Blood in Feces Is Associated With an Increased Risk of Ischemic Stroke and Myocardial Infarction
StudyGraphics

#VisualAbstract: Carboplatin holds potential as an adjunct therapy for recurrent high-grade glioma treatment

January 14, 2021
Next Post
Parents often unaware of adolescents’ suicidal thoughts

Psilocybin does not significantly improve depressive scores compared to escitalopram

Stem cell transplant may be effective in sickle cell disease

Poloxamer 188 not effective for acute management of vaso-occlusive episodes in patients with sickle cell disease

Compliance-linked incentives increase infant immunizations rates in rural India

ChAdOx1 nCoV-19 (AstraZeneca) vaccine is effective against the SARS-CoV-2 B.1.1.7 variant

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.